Business description
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturer, with a significant presence in North America and Japan. The company's core business centers on pharmaceutical products, emphasizing cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo explores merger and acquisition investments to enhance its research, development, manufacturing, and marketing capabilities as part of its growth strategy.
Management board & Supervisory board
| CEO |
| Hiroshi Nomura |
| Management board |
| Hideyuki Harada, Atsuko Higuchi, Takuya Taguchi, Koichi Kozuki, Isao Shimizu, Yumi Sato, Kenji Ueno, Naoki Noguchi, Tsutomu Nakagawa, Myrtle Potter, Adele Gulfo, Armin Szegedi |
| Supervisory board |
| Hiroshi Nomura, Toru Kimura, Yoshiharu Ikeda, Hiroyuki Baba, Shigeyuki Nishinaka, Saeko Arai, Nobuhiro Endo, Minoru Usui, Koji Fujimoto, Takashi Kutsunai, Hisayoshi Kashima, Yoshio Iteya, Mayumi Mochizuki, Daishiro Michimori |
Company data
| Name: |
Sumitomo Dainippon Pharma Co Ltd |
| Address: |
6-8, Doshomachi 2-chome Chuo-ku,Osaka 541-0045 |
| Phone: |
+81-6-6203-5321 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.sumitomo-pharma.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
03-31 |
| Free Float: |
- |
| IPO date: |
- |
Investor relations
| Name: |
- |
| IR phone: |
+81-120-782-031 |
| IR Fax: |
- |
| IR e-mail: |
-
|
